Cancer Family
Malignant Soft Tissue Neoplasm
CI-CAN-00000251Explore in graph →
341 active trials9 approved drugs37 evidence items
- NCIt
- C4867
Loading cancer entity…
Cancer Family
CI-CAN-00000251Explore in graph →
Clinical trials
1,396 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (200)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07291297 | Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma | recruiting | Phase 2 | 50 | Wake Forest University Health SciencesOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07507773 | Assessment of the Long-term Efficacy of Moderately Hypofractionated Neoadjuvant Radiotherapy Soft Tissue Sarcoma in the Limbs or Trunk Wall(NEORASARC) | recruiting | Phase 2 | 135 | Centre Oscar LambretOTHER |
| 1 |
| Jul 23, 2026 |
| clinicaltrials |
| NCT03400826 | Effects of Simvastatin on Uterine Leiomyoma Size | active not recruiting | Phase 2 | 60 | Johns Hopkins UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04022213 | A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum | active not recruiting | Phase 2 | 31 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03069378 | A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma | active not recruiting | Phase 2 | 41 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06660810 | Neoadjuvant Intralesional Injection of Talimogene Laherparepvec | active not recruiting | Phase 2 | 2 | John RiethOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07064018 | Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 67 | University of California, IrvineOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT05286801 | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | active not recruiting | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 3 | Jul 14, 2026 | clinicaltrials |
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | recruiting | Phase 1 / Phase 2 | 29 | University of FloridaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT03213652 | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 4 | Jul 10, 2026 | clinicaltrials |
| NCT02650986 | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | active not recruiting | Phase 1 / Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06327477 | Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma | recruiting | Phase 1 / Phase 2 | 28 | Northwestern UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT03972930 | Hypofractionated Radiotherapy for Soft Tissue Sarcomas | active not recruiting | Phase 2 | 48 | University of Wisconsin, MadisonOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06981637 | Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)(MELODY) | recruiting | Phase 2 | 81 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04195555 | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 3 | Jul 1, 2026 | clinicaltrials |
| NCT04416568 | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | active not recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06625190 | Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | University of FloridaOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04673942 | A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors(BETA-PRIME) | active not recruiting | Phase 2 | 140 | EpicentRx, Inc.INDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05180695 | HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas(AMPHISARC) | active not recruiting | Phase 1 / Phase 2 | 47 | Centre Leon BerardOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06571734 | XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma | recruiting | Phase 2 | 73 | Northwestern UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT03213704 | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07647198 | FATIMA Trial: EGCG and Vitamin D3 for Prevention of Fibroid Recurrence(FATIMA) | recruiting | Phase 2 | 240 | Sheikh Shakhbout Medical CityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07650838 | OVV-01 Injection Combined With AK112 Injection for the Treatment of Patients With Advanced Soft Tissue Sarcoma (STS) | not yet recruiting | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jun 16, 2026 | clinicaltrials |
| NCT07647068 | Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors | not yet recruiting | Phase 2 | 59 | Joal BeaneOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04589741 | Toripalimab Combined With CAV/IE Regimen | recruiting | Phase 2 | 134 | Sun Yat-sen UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06087861 | 5-Day Preoperative Radiation for Soft Tissue Sarcoma | recruiting | Phase 2 | 75 | Stanford UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05167994 | Preoperative IMRT With Anlotinib and Penpulimab for Localized Sarcoma (SPARE-01)(SPARE-01) | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06022159 | A Study to Evaluate Pre-operative HYPOfractionated Radiation Therapy in Aged (≥ 70 Years Old) or "Fragile" (≥ 65 Years) Patients With Limb or Trunk Soft Tissue SARComa.(HYPOSARC) | recruiting | Phase 2 | 48 | Institut Claudius RegaudOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07539454 | Nirogacestat in Patients With Kaposi Sarcoma | not yet recruiting | Phase 2 | 28 | AIDS Malignancy ConsortiumNETWORK | 1 | May 28, 2026 | clinicaltrials |
| NCT07612098 | Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue Sarcoma(SPARE-04) | not yet recruiting | Phase 2 | 274 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT03114527 | Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) | active not recruiting | Phase 2 | 48 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07467772 | Ph 2 Elacestrant in ER Positive Uterine Sarcomas | recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07602049 | Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 57 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04901702 | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | recruiting | Phase 1 / Phase 2 | 90 | St. Jude Children's Research HospitalOTHER | 2 | May 19, 2026 | clinicaltrials |
| NCT06094101 | Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)(PerVision) | recruiting | Phase 1 / Phase 2 | 30 | University Hospital TuebingenOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04200443 | Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma | active not recruiting | Phase 2 | 96 | City of Hope Medical CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04605770 | Pemetrexed, Cisplatin With Soft Tissue Sarcoma(ALBATROSS) | recruiting | Phase 2 | 164 | Yonsei UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07243626 | Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 25 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT04332874 | A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07548177 | Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma | recruiting | Phase 2 | 33 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05836571 | Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma | active not recruiting | Phase 2 | 66 | National Cancer Institute LAOUNKNOWN | 2 | Apr 21, 2026 | clinicaltrials |
| NCT04028063 | Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas | active not recruiting | Phase 2 | 65 | University of Colorado, DenverOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04189783 | Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial) | active not recruiting | Phase 2 | 113 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05407441 | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | active not recruiting | Phase 1 / Phase 2 | 49 | Susan Chi, MDOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05926700 | Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment | recruiting | Phase 2 | 27 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 8, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 23, 2026source: clinicaltrials